First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects
Jingyi Wang, Lin Wu
Abstract
Global Cancer Statistics 2022 reported the prevalence and high mortality rate of lung cancer. Notably, non-small cell lung cancer (NSCLC) accounts for the majority of the histologic types[1][1]. Precision therapy for lung cancer has progressed rapidly and immune checkpoint inhibitors (ICIs) have
Topics & Concepts
Lung cancerImmunotherapyMedicineOncologyCancerInternal medicineCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesLung Cancer Research Studies